- Home
- PCTY vs CORT Comparison
PCTY vs CORT Comparison
Compare PCTY & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCTY
- CORT
- Stock Information
- Founded
- PCTY 1997
- CORT 1998
- Country
- PCTY United States
- CORT United States
- Employees
- PCTY N/A
- CORT N/A
- Industry
- PCTY Computer Software: Prepackaged Software
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- PCTY Technology
- CORT Health Care
- Exchange
- PCTY Nasdaq
- CORT Nasdaq
- Market Cap
- PCTY 9.9B
- CORT 8.8B
- IPO Year
- PCTY 2014
- CORT N/A
- Fundamental
- Price
- PCTY $154.75
- CORT $89.45
- Analyst Decision
- PCTY Buy
- CORT Strong Buy
- Analyst Count
- PCTY 18
- CORT 4
- Target Price
- PCTY $221.06
- CORT $139.00
- AVG Volume (30 Days)
- PCTY 592.2K
- CORT 940.0K
- Earning Date
- PCTY 10-29-2025
- CORT 10-29-2025
- Dividend Yield
- PCTY N/A
- CORT N/A
- EPS Growth
- PCTY 10.74
- CORT N/A
- EPS
- PCTY 4.02
- CORT 1.11
- Revenue
- PCTY $1,595,221,000.00
- CORT $716,080,000.00
- Revenue This Year
- PCTY $9.77
- CORT $30.77
- Revenue Next Year
- PCTY $8.97
- CORT $37.75
- P/E Ratio
- PCTY $38.38
- CORT $79.36
- Revenue Growth
- PCTY 13.74
- CORT 25.71
- 52 Week Low
- PCTY $151.71
- CORT $42.01
- 52 Week High
- PCTY $223.80
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- PCTY 28.01
- CORT 77.61
- Support Level
- PCTY $151.96
- CORT $82.70
- Resistance Level
- PCTY $157.45
- CORT $90.71
- Average True Range (ATR)
- PCTY 3.85
- CORT 2.28
- MACD
- PCTY -0.65
- CORT 0.72
- Stochastic Oscillator
- PCTY 5.08
- CORT 96.01
About PCTY Paylocity Holding Corporation
Founded in 1997, Paylocity is a cloud-based human capital management and payroll platform servicing midmarket customers. The company's average client size is around 150 employees. Its products help with recruiting and onboarding, payroll, time and labor, human resources, benefits, learning, and performance and compensation workflows. In fiscal 2025, the company generated over $1.5 billion in revenue across more than 41,000 customers.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.